(BDX) Becton, Dickinson and Co Reports Strong Results
Becton, Dickinson and Co. (BDX) reported strong fourth quarter and full fiscal 2009 results. For the fourth quarter, earnings per share were $1.25, beating the Zacks Consensus Estimate by a cent and...
View Article(CFN) CareFusion Corporation Enters Agreement with Masimo
CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and...
View Article(BDX) Becton, Dickinson and Company Acquires HandyLab
Becton, Dickinson and Company (BDX) recently completed the acquisition of HandyLab, Inc, an Ann Arbor, Michigan-based company that develops and manufactures automation platforms and molecular...
View Article(MASI) Masimo Corporation Renews Deal with Advocate Health Care
Masimo Corporation (MASI) announced that one of its prominent customers, Advocate Health Care, has recently renewed its multi-year, system-wide contract for Masimo SET pulse oximetry technology....
View Article(MASI) Masimo Corporation Earns FDA New Product Approval
Masimo Corporation (MASI) recently received the U.S. Food and Drug Administration (FDA) approval for its new product, Masimo Rainbow SET Acoustic Monitoring. The new product enables noninvasive and...
View Article(BAX) Baxter International Gets H1N1 Vaccine Order
Baxter International Inc. (BAX) recently received another order for 10,000 H1N1 vaccines, commonly known as “swine flu,” from Slovenia. The order is worth $158,700 (105,000 euros). It is estimated that...
View Article(BDX) Becton, Dickinson and Co Receives FDA Clearance
Becton, Dickinson and Co. (BDX) recently announced that BD Diagnostics, a segment of BDX, has received U.S. Food and Drug Administration (FDA) clearance to utilize its BD ProbeTec Chlamydia trachomatis...
View Article(MASI) Masimo Completes Conversion of New Customer
Masimo Corp. (MASI) reported that its new customer, Brookdale University Hospital and Medical Center in Brooklyn, New York, has completed its system-wide conversion to Masimo SET pulse oximetry...
View Article(MASI) Masimo Corporation in Expansion Mode
Masimo Corp. (MASI) recently announced the expansion of its corporate campus in Irvine, California with the addition of an adjacent 32,000 sq. ft. building. This is the company’s third building on its...
View Article(MASI) Masimo Corporation Can Now Earn While Patients Test Device Effectiveness
Masimo Corporation (MASI) has recently received a new Current Procedural Terminology (CPT) code from the American Medical Association, 88738, for its noninvasive hemoglobin (SpHb) measurement. Medicare...
View Article(MASI) Masimo Corporation Announces Positive Results From Clinical Study
Masimo Corporation (MASI) recently announced positive results form its 21-month clinical study on the impact of the Masimo Patient SafetyNet remote monitoring and clinician notification system. Results...
View Article(BAX) Baxter International Reports Earnings In-Line
Baxter International Inc. (BAX) reported financial results for the fourth quarter and full fiscal 2009. For the fourth quarter, earnings per share were $1.03, in line with the Zacks Consensus Estimate...
View Article(BDX) Becton Dickinson and Company Surpasses Consensus Estimates
Becton, Dickinson and Company (BDX) reported first quarter fiscal 2010 earnings per share of $1.30, surpassing the Zacks Consensus Estimate of $1.20 and the year-ago earnings of $1.25. Total Revenues...
View Article(MDRX) Medical Devices Stock Review – Feburary 2010 – Industry Outlook
The global medical devices industry is fairly large, with annual worldwide sales in excess of $200 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into...
View Article(BDX) Becton, Dickinson and Company Beats Expectations – Bumps Estimates
We recently reiterated our Neutral rating on Becton, Dickinson and Company (BDX) with a target price of $78 based on a P/E of approximately 15.3x our fiscal 2010 EPS estimate of $5.10. Becton recently...
View Article(BAX) Baxter International Downgraded to Neutral
We recently downgraded Baxter International Inc. (BAX) to Neutral. The stock was assigned a target price of $59 based on an approximate P/E multiple of 13.9x our fiscal 2010 earnings estimate of $4.25....
View Article(BDX) Becton, Dickinson and Company Recalls Catheters
Becton, Dickinson and Company (BDX) recently started expanding the recall of its catheters as a result of a manufacturing problem that could cause fatal embolisms or blood leakage. Becton is recalling...
View Article(MASI) Masimo Analysts Maintain Neutral Rating
We continue to maintain our ‘Neutral’ rating on Masimo Corp. (MASI) with a target price of $28 based on a P/E of 28.0x our fiscal 2010 EPS estimate of $1. The company’s fourth quarter fiscal 2009...
View Article(BAX) Baxter International Receives FDA Approval for TachoSil
Baxter International Inc. (BAX) and Nycomed recently received the U.S. Food and Drug Administration (FDA) approval of TachoSil, an absorbable fibrin sealant patch that can be used in addition to...
View Article(BAX) Baxter International Posts Encouraging Clinical Study Results
Baxter International Inc. (BAX) recently produced encouraging results of its 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D (Immune Globulin Intravenous [Human]) for...
View Article
